55 completed, 5 terminated, 3 withdrawn, 2 unknown. 67 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 67 | Completed 55, Terminated 5, Withdrawn 3, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Donepezil: new trials by email Literature Review of Donepezil trials Research Report on Donepezil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD) E2511, Donepezil - Alzheimers Disease | Phase 1 | Not yet recruiting | Eisai Inc. | 32 | 2026-10-15 | 2026-08-17 |
| Pharmacokinetic Study of GB-5001A 280 mg Long Acting Injection, in Comparison With the Comparator Drug Aricept® 5 mg and Aricept® 10 mg Film-coated Tablet in Healthy Subjects GB-5001A 280 mg long acting Injection, Aricept® 5 mg film-coated tablet, Aricept® 10 mg film-coated tablet - Bioavailability Study on Healthy Volunteers | Phase 1 | Completed | G2GBio, Inc. | 28 | 2025-08-12 | 2026-09-02 |
| Phenserine on the Alzheimer's Treatment Horizon, Study 1 Phenserine, Donepezil (Aricept®) - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | Completed | Helse Stavanger HF | 16 | 2025-02-01 | 2026-05-04 |
| Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) MK-1167, Donepezil, Placebo - Alzheimer's Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 28 | 2024-03-28 | 2025-10-14 |
| A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003. Aricept Tablet, IVL3003 - Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Inventage Lab., Inc. | 62 | 2023-04-01 | 2024-12-19 |
| Phase 1 Clinical Trial of DA-5207 in Healthy Adults Aricept 5mg Tablet, Aricept 10mg Tablet, DA-5207 A - Healthy | Phase 1 | Completed | Dong-A ST Co., Ltd. | 51 | 2021-11-25 | 2023-04-14 |
| Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413) Donepezil, Placebo - Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | Completed | Merck Sharp & Dohme LLC | 44 | 2021-03-23 | 2024-10-28 |
| MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) MK-1942, Donepezil, Placebo - Alzheimer's Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 27 | 2021-02-16 | 2024-08-15 |
| Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers Donepezil TDS, Aricept - Healthy Subjects | Phase 1 | Completed | Corium, Inc. | 60 | 2020-12-08 | 2024-09-19 |
| Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults Aricept 5mg Tablet, Aricept 10mg Tablet, DA-5207 150mg - Healthy | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 49 | 2020-07-28 | 2021-04-15 |
| Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) MK-4334, Placebo to MK-4334, Donepepzil - Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | Withdrawn | Merck Sharp & Dohme LLC | 2019-09-27 | 2025-04-25 | |
| Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects Donepezil Pamoate for Injection 17mg, Donepezil Pamoate for Injection 34mg, Donepezil Hydrochloride 5mg - AD | Phase 1 | Completed | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | 38 | 2019-07-02 | 2020-09-29 |
| Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and PK of DA-5207 TDS in Healthy Adults DA-5207, Donepezil Hydrochloride - Healthy | Phase 1 | Completed | Dong-A ST Co., Ltd. | 40 | 2019-06-18 | 2021-04-14 |
| A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other BI 425809, Donepezil - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 32 | 2019-04-12 | 2021-02-17 |
| A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease AGN-242071, Placebo, Donepezil - Alzheimer's Disease | Phase 1 | Withdrawn | Allergan | 2018-09-30 | 2018-11-02 | |
| A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers THN 201, Donepezil, Placebo - Cognitive Impairment, Alzheimer Disease | Phase 1 | Completed | Theranexus | 152 | 2018-09-27 | 2020-01-22 |
| CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1) Memantine Tab. 10mg, Memantine Tab. 10mg + Donepezil Tab. 10mg - Central Nervous System Diseases | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 20 | 2018-04-16 | 2018-06-26 |
| A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept® Donepezil TDS, Aricept - Alzheimer's Disease | Phase 1 | Completed | Corium, Inc. | 86 | 2017-10-30 | 2018-08-01 |
| Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers BPN14770, BPN14770 placebo, Donepezil - Alzheimer Disease | Phase 1 | Completed | Tetra Discovery Partners | 38 | 2017-01-01 | 2018-10-16 |
| TAK-071 Scopolamine-Induced Cognitive Impairment Study Scopolamine, TAK-071, Donepezil - Healthy Volunteers | Phase 1 | Terminated | Takeda | 18 | 2016-11-21 | 2019-06-14 |
Showing 20 of 67. Sign in to see all of them.
Alzheimer Disease (27) · Cognitive Dysfunction (8) · Dementia (4) · Memory Disorders (3) · Central Nervous System Diseases (2) · Stroke (2) · Amblyopia (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Cognition Disorders (1) · Dementia, Vascular (1) · Fragile X Syndrome (1) · Hyperalgesia (1)
Merck Sharp & Dohme LLC (8) · AstraZeneca (4) · Dr. Reddy's Laboratories Limited (4) · Teva Pharmaceuticals USA (4) · Corium, Inc. (3) · Dong-A ST Co., Ltd. (3) · Eisai Co., Ltd. (3) · Boehringer Ingelheim (2) · Eisai Inc. (2) · Pfizer (2) · Ranbaxy Laboratories Limited (2) · Takeda (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Allergan (1) · Boston Children's Hospital (1)
United States (26) · France (8) · South Korea (7) · Canada (4) · United Kingdom (4) · Japan (3) · Australia (2) · Germany (2) · India (2) · China (1) · Indonesia (1) · Netherlands (1) · Norway (1)
Benoit J Deschamps, M.D. (2) · Danielle Armas, MD (2) · Dr. L Krishna Murthy (2) · Eric Sicard, MD (2) · Hiroki Shimizu (2) · James D Carlson, Pharm.D. (2) · A. M. Barrett, MD (1) · Allan L Reiss (1) · Beth Safirstein, M.D. (1) · Bharti Gangwani, MD (1)
PMID 21644059, PMID 21723605, PMID 25218827, PMID 36120781
2015 (1), 2018 (1)